Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report

  • Prolonged-release fampridine (PR-FAM), a potassium channel blocker, is approved for improving walking ability in patients with multiple sclerosis (MS). Beyond this, positive effects on other MS symptoms like fatigue, cognition, and tremor have been described. To our knowledge, a positive effect of PR-FAM on spinal myoclonus has not been described so far. Here, we report a 32-year-old female with myoclonus after cervical myelitis affecting both hands which markedly improved after administration of PR-FAM. Treatments used before such as carbamazepine or levetiracetam had to be withdrawn because of intolerable side effects or lack of efficacy. The positive effect of PR-FAM could be confirmed by transient suspension. PR-FAM may be considered as a treatment option in refractory spinal myoclonus after myelitis in selected cases.

Download full text files

Export metadata


Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Author:Mona Klara Ros Müller, Monika ChristGND, Markus NaumannGND, Antonios BayasORCiDGND
Frontdoor URL
Parent Title (English):Therapeutic Advances in Neurological Disorders
Publisher:SAGE Publications
Year of first Publication:2022
Publishing Institution:Universität Augsburg
Release Date:2022/05/18
Tag:Neurology (clinical); Neurology; Pharmacology
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Neurologie
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Latest Publications (not yet published in print):Aktuelle Publikationen (noch nicht gedruckt erschienen)
Licence (German):CC-BY-NC 4.0: Creative Commons: Namensnennung - Nicht kommerziell (mit Print on Demand)